Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report)'s share price dropped 6.2% on Thursday . The company traded as low as $10.05 and last traded at $10.05. Approximately 159,950 shares traded hands during trading, a decline of 79% from the average daily volume of 779,765 shares. The stock had previously closed at $10.71.
Analysts Set New Price Targets
OLMA has been the subject of a number of recent research reports. The Goldman Sachs Group initiated coverage on Olema Pharmaceuticals in a research report on Tuesday, April 2nd. They set a "buy" rating and a $24.00 price objective for the company. Citigroup initiated coverage on Olema Pharmaceuticals in a research report on Tuesday, January 30th. They set a "buy" rating and a $20.00 price objective for the company. Finally, Capital One Financial reissued an "overweight" rating on shares of Olema Pharmaceuticals in a research note on Thursday, February 22nd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $21.43.
Check Out Our Latest Stock Analysis on Olema Pharmaceuticals
Olema Pharmaceuticals Price Performance
The firm has a 50-day simple moving average of $12.52 and a two-hundred day simple moving average of $12.95. The company has a market cap of $553.61 million, a PE ratio of -4.58 and a beta of 2.10.
Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last posted its quarterly earnings data on Monday, March 11th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). Equities research analysts forecast that Olema Pharmaceuticals, Inc. will post -2.34 EPS for the current year.
Insider Transactions at Olema Pharmaceuticals
In other news, Director Cyrus Harmon sold 25,000 shares of the firm's stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $12.41, for a total transaction of $310,250.00. Following the sale, the director now owns 846,283 shares in the company, valued at $10,502,372.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 70,000 shares of company stock worth $835,400 over the last quarter. 23.50% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Olema Pharmaceuticals
Several hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Olema Pharmaceuticals by 58.2% during the fourth quarter. Vanguard Group Inc. now owns 2,705,895 shares of the company's stock worth $37,964,000 after purchasing an additional 995,588 shares during the last quarter. Perceptive Advisors LLC acquired a new position in Olema Pharmaceuticals in the fourth quarter valued at $7,574,000. Virtus ETF Advisers LLC acquired a new position in Olema Pharmaceuticals in the fourth quarter valued at $105,000. Legal & General Group Plc boosted its holdings in Olema Pharmaceuticals by 910.8% in the fourth quarter. Legal & General Group Plc now owns 24,533 shares of the company's stock valued at $344,000 after acquiring an additional 22,106 shares during the last quarter. Finally, Barclays PLC boosted its holdings in Olema Pharmaceuticals by 831.8% in the fourth quarter. Barclays PLC now owns 43,396 shares of the company's stock valued at $609,000 after acquiring an additional 38,739 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company's stock.
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Stories
Before you consider Olema Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Olema Pharmaceuticals wasn't on the list.
While Olema Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
